학술논문

Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study
Document Type
Article
Source
The Lancet Haematology; March 2020, Vol. 7 Issue: 3 pe196-e208, 13p
Subject
Language
ISSN
23523026
Abstract
The PROUD-PV and CONTINUATION-PV trials aimed to compare the novel monopegylated interferon ropeginterferon alfa-2b with hydroxyurea, the standard therapy for patients with polycythaemia vera, over 3 years of treatment.